MiniMed Surpasses $3B in Annual Sales, Eyes Growth with New Product Launches
Event summary
- MiniMed reported $3.1B in annual net sales, a 14% increase, surpassing $3B for the first time.
- Q4 net sales grew 16% year-over-year to $837M, with international sales up 22.4%.
- FDA cleared MiniMed Flex™ and CE Mark approved Instinct sensor for global launch.
- Company expects 10% organic revenue growth for FY2027, with adjusted EBITDA margin of ~16%.
- MiniMed Go™ Smart MDI system launched in the U.S., with Flex™ pre-orders starting this week.
The big picture
MiniMed's strong fiscal year performance underscores its leadership in diabetes technology, driven by international expansion and product innovation. The company's strategic focus on next-generation insulin delivery systems and continuous glucose monitoring (CGM) positions it to capitalize on the growing demand for integrated diabetes management solutions. With a robust pipeline and recent regulatory milestones, MiniMed is well-positioned to maintain its competitive edge in a rapidly evolving market.
What we're watching
- Product Adoption
- How the launches of MiniMed Flex™ and MiniMed Go™ will drive long-term growth acceleration.
- Market Expansion
- Whether MiniMed can sustain its international momentum, particularly in high-growth regions.
- Regulatory Dynamics
- The pace at which MiniMed can secure additional regulatory approvals for its pipeline products.